Sermorelin vs Tesamorelin
Updated 13 sources
Key differences
- 1Tesamorelin is full-length GHRH(1-44) with a stabilizer. It is currently approved and has Phase 3 visceral-fat data. Sermorelin's approval is discontinued.
- 2Both are GHRH-based. Sermorelin is the 1-29 fragment and its approval was discontinued. Tesamorelin is full length and currently approved.
Side by side
Facts from each record, in the same words as their own pages.
| Sermorelin | Tesamorelin | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
13 sources, each checked by date. Record updated Oct 23, 2026. Numbers are restated in our own words and labelled by where they came from.
Clinical study4
- Tesamorelin pooled Phase 3 (Falutz 2010)PubMed · checked Oct 23, 2026
- Sermorelin review (Prakash & Goa 1999)PubMed · checked Oct 23, 2026
- hGRF1-29NH2 plasma levels after IV and SC (Rafferty 1985)PubMed · checked Oct 23, 2026
- Performance-enhancing peptides modulating GH-IGF1 axis (Dominikowski 2026)PMC · checked Oct 23, 2026
Regulatory6
- Drugs@FDA Geref records (openFDA)FDA · checked Oct 23, 2026
- Egrifta SV labelDailyMed · checked Oct 23, 2026
- Egrifta WR labelDailyMed · checked Oct 23, 2026
- Determination that Geref was not withdrawn for safety or effectivenessFederal Register · checked Oct 23, 2026
Competitor guide3
- SermorelinPeptidesExplorer · checked Oct 23, 2026
- Sermorelin dosage guideBodyHackGuide · checked Oct 23, 2026
- Sermorelin dosage guidePeptideDeck · checked Oct 23, 2026